Literature DB >> 29502563

Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population.

Michele F Eisenga1, Lyanne M Kieneker2, Daan J Touw3, Ilja M Nolte4, Peter van der Meer5, Gerwin Huls6, Carlo A J M Gaillard7, Stephan J L Bakker2.   

Abstract

Cigarette smoking continues to be one of the major risk factors for increased morbidity and mortality worldwide. Among many adverse health effects, smoking can induce erythrocytosis, which is commonly believed to result from elevated serum erythropoietin (EPO) levels. Currently, however, this notion is only alleged, without data available to substantiate it. Hence, we analyzed data from the Prevention of Renal and Vascular End-Stage Disease study, a prospective population-based cohort study. Smoking behavior was quantified as number of cigarettes smoked per day and as 24-hour urinary cotinine excretion levels, an objective and quantitative measure of nicotine exposure. In 6808 community-dwelling participants, the prevalence of nonsmokers, former smokers, and current smokers were 29%, 43%, and 28%, respectively. Hematocrit levels were higher in current smokers (41.4%±3.6%) than in nonsmokers (40.3%±3.6%) (P<.001). In contrast, median EPO levels were lower in current smokers (7.5 IU/L; interquartile range [IQR], 5.7-9.6 IU/L) than in nonsmokers (7.9 IU/L; IQR, 6.0-10.7 IU/L) (P<.001). In multivariate linear regression analysis, current smoking, compared with nonsmoking, was independently positively associated with hematocrit levels (β=.12; P<.001) and hemoglobin levels (β=.11; P<.001), but inversely associated with EPO levels (β=-.09; P<.001). In sensitivity analyses, we observed a dose-dependent inverse association of smoking exposure reflected by 24-hour urinary cotinine excretion levels with EPO levels. Contrary to common belief, we identified that in the general population, smoking is inversely associated with EPO levels. Future mechanistic insight is needed to unravel the currently identified association, and if reproduced in other studies, guidelines for diagnosis of secondary erythrocytosis may need to be revisited.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29502563     DOI: 10.1016/j.mayocp.2018.01.005

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

1.  Cigarette smoking and complications in elective thoracolumbar fusions surgery: An analysis of 58,304 procedures.

Authors:  Zachary T Sharfman; Yaroslav Gelfand; Henry Hoang; Rafael De La Garza Ramos; Jaime A Gomez; Jonathan Krystal; David Kramer; Reza Yassari
Journal:  J Craniovertebr Junction Spine       Date:  2022-06-13

2.  Effect of nonsurgical periodontal therapy and smoking status on hematological variables related to anemia of chronic disease in chronic periodontitis patient: a case-control study.

Authors:  Sangita Show; Somen Bagchi; Arka Kanti Dey; Ramanarayana Boyapati; Pritish Chandra Pal; Kanikanti Siva Tejaswi
Journal:  J Yeungnam Med Sci       Date:  2022-05-16

3.  Age-dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients.

Authors:  David Montero; Thomas Haider; Jens Barthelmes; Jens P Goetze; Silviya Cantatore; Carsten Lundby; Isabella Sudano; Frank Ruschitzka; Andreas J Flammer
Journal:  Physiol Rep       Date:  2019-03

4.  Association between lifestyle and hematological parameters: A study of Chinese male steelworkers.

Authors:  Mei-Chu Yen Jean; Chia-Chang Hsu; Wei-Chin Hung; Yung-Chuan Lu; Chao-Ping Wang; I-Ting Tsai; I-Cheng Lu; Yi-Hsin Hung; Fu-Mei Chung; Yau-Jiunn Lee; Teng-Hung Yu
Journal:  J Clin Lab Anal       Date:  2019-06-26       Impact factor: 2.352

5.  Tobacco smoking causes secondary polycythemia and a mild leukocytosis among heavy smokers in Taif City in Saudi Arabia.

Authors:  Adel Qlayel Alkhedaide
Journal:  Saudi J Biol Sci       Date:  2019-11-18       Impact factor: 4.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.